Abstract
Invasive candidiasis is a common infectious complication in intensive care units and hematological malignancies chemotherapy units. This study presents data from the first-in-Russia health economics review of the anidulafungin use in the treatment of adults with candidiasis compared to standard and alternative therapies. The main study method was modeling based on a literature review of data on the use of antifungals in high-risk patients for fungal infection. Both primary and alternative scenarios as well as one-sided sensitivity analysis and likelihood analysis (Monte Carlo simulation) were used. Results from this pharmacoeconomic analysis suggest that the use of anidulafungin in the treatment of adult patients with invasive candidiasis is reasonable. The advantages of anidulafungin over other antifungals in the treatment of invasive candidiasis were as follows: the lowest direct costs, the highest efficacy outcomes, and the most favorable cost-effectiveness.
-
1.
Kett D.H., Shorr A.F., Reboli A.C., et al. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011; 15(5):R253.
-
2.
Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии. Российские национальные рекомендации. Под ред. Н.Н.Климко. – Москва, 2010 г. – 92 с.
-
3.
Groll A.H., Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46(3):212-29.
-
4.
Kullberg B.J., Verweij P.E., Akova M., et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 2011; 17(Suppl. 5):1-12.
-
5.
Pappas P., Kauffman C., Andes D., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 1:48(5):503-35.
-
6.
Gilbert D.N., Moellering R.C., Epiopoulos G.M., editors. The Sanford guide to antimicrobial therapy. 42nd Edition; 2012.
-
7.
Система стандартизации в здравоохранении Российской Федерации. «Отраслевой стандарт клинико-экономического исследования. Общие положения» (ОСТ 91500.14.0001-2002). Министерство здравоохранения Российской Федерации. Приказ от 27 мая 2002 года № 163.
-
8.
Авксентьева М.А., Герасимов В.Б., Сура М.В. Клиникоэкономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). Под ред. П.А. Воробьева. – М.: Ньюдиамед, 2004. – 404 с.
-
9.
Планирование и проведение клинических исследований лекарственных средств / Белоусов Ю.Б. [и др.]. – М.: Общество клинических исследователей, 2000. - 579 с.
-
10.
Walley T., Haycox A., Boland A. (Eds.). Pharmacoeconomics. Elsevier Health Sciences, 2004.
-
11.
Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. (Eds.). Cost-effectiveness in Health and Medicine. New York: Oxford University Press. 1996.
-
12.
Ягудина Р.И., Куликов А.Ю., Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. Фармакоэкономика 2011; 4(1):7-12.
-
13.
Бюллетень для оптовых покупателей и поставщиков медикаментов «Фарминдекс». – 2012 (www.pharmindex.ru).
-
14.
http://zakupki.gov.ru.
-
15.
http://grls.rosminzdrav.ru.
-
16.
Maertens J., Marchetti O., Herbrecht R., et al. European guidelines for antifungal man-agement in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Tr 2010:1-10.
-
17.
Dupont B.F., Lortholary O., Ostrosky-Zeichner L., et al. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13(5):R159.
-
18.
Concia E., Azzini A.M., Conti M. Epidemiology, incidence and risk factors for invasive candidiasis in highrisk patients. Drugs 2009; 69.
-
19.
Weinstein M., O’Brien B., Hornberger J., et al. Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies.Value Health 2003; 6:9-17.
-
20.
Клиническая эпидемиология. Основы доказательной медицины. Пер. с англ. под ред. Р. Флетчер, С. Флетчер, Э. Вагнер. – М. : Медиа Сфера, 1998. – 347 с.
-
21.
Evidence-based medicing working group. Evidencebased medicine. A new approach to teaching the practice of medicine. JAMA 1992; 258:2420-5.
-
22.
Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337 -45.
-
23.
Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020–9.
-
24.
Rex J., Pappas P., Karchmer A., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221–8.
-
25.
Ostrosky-Zeichner L., Oude Lashof A., Kullberg B., et al. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651–5.
-
26.
Krause D.S., Goldstein B.P., Wible M., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48:2021-4.
-
27.
Kullberg B., Sobel J., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366(9495):1435-42.
-
28.
Reboli A., Rotstein C., Pappas P., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472–82.
-
29.
Pappas P., Rotstein C., Betts R., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883–93.
-
30.
Kuse E.R., Chetchotisakd P., da Cunha CA., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 2007; 369(9572):1519-27.
-
31.
Bal A.M. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 2010; 35(1):13- 8.
-
32.
Веселов А.В., Климко Н.Н, Кречикова О.И. и др. In vitro активность флуконазола и вориконазола в отношении более 10 000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России. Клин микробиол антимикроб химиотер 2008; 10(4):345-54.
-
33.
Glöckner A., Steinbach A., Vehreschild J.J., et al. Treatment of invasive candidiasis with echinocandins. Mycoses 2009; 52(6):476-86.